Head-To-Head Analysis: ABVC BioPharma (NASDAQ:ABVC) & Northwest Biotherapeutics (OTCMKTS:NWBO)

Northwest Biotherapeutics (OTCMKTS:NWBO) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Risk and Volatility

Northwest Biotherapeutics has a beta of -0.84, indicating that its share price is 184% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

Valuation & Earnings

This table compares Northwest Biotherapeutics and ABVC BioPharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northwest Biotherapeutics	$1.38 million	266.25	-$83.78 million	($18.26)	-0.01
ABVC BioPharma	$510,000.00	100.54	-$4.90 million	($0.20)	-10.55

ABVC BioPharma has lower revenue, but higher earnings than Northwest Biotherapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.0% of Northwest Biotherapeutics shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 2.4% of Northwest Biotherapeutics shares are owned by insiders. Comparatively, 17.1% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Northwest Biotherapeutics and ABVC BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northwest Biotherapeutics	-9,580.90%	N/A	-313.92%
ABVC BioPharma	N/A	-50.42%	-27.52%

Analyst Ratings

This is a breakdown of current recommendations for Northwest Biotherapeutics and ABVC BioPharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Northwest Biotherapeutics	0	0	0	0	0.00
ABVC BioPharma	1	0	0	0	1.00

Summary

ABVC BioPharma beats Northwest Biotherapeutics on 8 of the 12 factors compared between the two stocks.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About ABVC BioPharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.